BRILINTA Receives Additional Class I Recommendation in Updated ACCF/AHA Guidelines for the Management of UA/NSTEMI Patients

AstraZeneca

announced Monday that a combined panel of experts from the American College of Cardiology Foundation and American Heart Association have updated their guidelines to include a Class I recommendation for the use of the oral antiplatelet medicine, BRILINTA tablets in patients with Unstable Angina or Non–ST-Elevation Myocardial Infarction managed both invasively and non-invasively. “This Guidelines update is yet another strong recommendation for BRILINTA by clinical and scientific leadership within the Cardiology community. We are pleased that the Guidelines recognize the important benefits that BRILINTA provides in the treatment of a broad range of patients with UA/NSTEMI,” said James Ferguson, MD, Executive Director, Medical Affairs and Strategic Development, US, and Vice President for Global Medical Affairs. “This expert consensus is another valued milestone illustrating how our standards of care continue to evolve, and how medications, such as BRILINTA, can very quickly become an important part of those standards.”